A seroprevalence study of poliovirus antibody among primary schoolchildren in Korea

Epidemiology and Infection

Volumn 132, Issue 2, 2004, Pages 351-355

  Jee, Y M ^a   Cheon, D S ^a   Kim, K S ^a   Lee, S H ^a   Yoon, J D ^a   Lee, S W ^a   Go, U ^a   Yang, B K ^a   Ki, M R ^b   Choi, B Y ^c   Cho, H W ^a  

^a Korea National Institute of Health   (South Korea)

^b Eulgi University   (South Korea)

^c Hanyang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL POLIOMYELITIS VACCINE; VIRUS ANTIBODY;

ARTICLE; BLOOD SAMPLING; CELL CULTURE; CHILD; CONTROLLED STUDY; HUMAN; KOREA; MAJOR CLINICAL STUDY; MASS IMMUNIZATION; OUTCOMES RESEARCH; POLIOMYELITIS; POLIOMYELITIS VIRUS; SEROPREVALENCE; WORLD HEALTH ORGANIZATION;

ANTIBODIES, VIRAL; CHILD; HUMANS; KOREA; POLIOVIRUS; SEROEPIDEMIOLOGIC STUDIES; VACCINATION;

EID: 11144354066     PISSN: 09502688     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0950268803001663     Document Type: Article

References (16)

1. Minimal Requirements for Biological Products by the Association of Biological Manufacturers of the Republic of Korea, Korea Food and Drug Administration, 1999.
2. Polio laboratory manual. Department of Vaccines and Biologicals, World Health Organization, Geneva, 2001.
3. John TJ, Jayabal P. Oral polio vaccination of children in the tropics. The poor sero-conversion rates and the absence of viral interference. Am J Epidemiol 1972; 96: 263-269.
4. Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 1991; 13: 926-939.
5. Sutter RW, Suleiman AFM, Malankar P, et al. Trial of a supplemental dose of four poliovirus vaccines. New Engl J Med 2000; 343: 767-773.
6. Porta D, Chierchini P, Bruno L, et al. A seroepidemiological study on the level of immunological coverage in a nomadic population in Rome. Epidemiol Prev 1997; 21: 48-53.
7. Saraswathy TS, Sinniah M, Lee WS, Lye MS, Choo KE, Jusoh H. Poliomyelitis and measles serosurvey in northern Malaysia. Southeast Asian J Trop Med Pub Health 1994; 25: 565-568.
8. Borcic B, Kruzic V, Kaic B, Ljubin-Sternak S, Ljubicic M, Dobrovsak-Sourek V. Immunity of the Croatian population to poliomyelitis - a serosurvey. Acta Med Croatia 1998; 52: 229-233.
9. Conyn-Van Spaendonck MA, de Melker HE, Abbink F, Elzinga-Gholizadea N, Kimman TG, van Loon T. Immunity to poliomyelitis in the Netherlands. Am J Epidemiol 2001; 153: 207-214.
10. Diedrich S, Claus H, Thierfelder W, Bellach BM, Schreier E. German Health Survey 1997/98: Immune status against poliomyelitis. Dtsch Med Wochenschr 2000; 125: 584-588.
11. Schoub BD, McAnerney JM, Van Middelkoop A, Blackburn NK, Labadarios D. A population-based seroprevalence study in South Africa as a tool in the polio eradication initiative. Am J Trop Med Hyg 1998; 58: 650-654.
12. Chen RT, Hausinger S, Dajani AS, Hanfling M, et al. Seroprevalence of antibody against poliovirus in innercity preschool children. Implications for vaccination policy in the United States. JAMA 1996; 275: 1682-1683.
13. Sutter RW, Suleiman AJM, Malankar PG, et al. Sequential use of inactivated vaccine followed by oral poliovirus vaccine in Oman. J Infect Dis 1997; 175 (Suppl 1): S235-S240.
14. Anderson RM. The concept of herd immunity and the design of community-based immunization programmes. Vaccine 1992; 10: 928-935.
15. Immunisation Handbook 2002. Ministry of Health, New Zealand.
16. Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine-using countries. Weekly Epidemiological Record (2003), 11 July, no. 28, 2003; 78: 241-252.